Xbrane Biopharma AB (publ) (”Xbrane” or ”the Company”) (Nasdaq Stockholm: XBRANE) announces today change of date for the Interim Report for the fourth quarter 2021 as well as the 2021 Year-end Report, to February 24, 2022, from previously communicated February 16, 2022.

The Company hereby also invites to a phone conference for investors, analysts, and media on Thursday 24 February 2022 at 10:00 am CET when the Interim report will be presented.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.3bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally four biosimilar candidates in its pipeline targeting € 24.3bn in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.
For more information, visit www.xbrane.com.

Attachments

Xbrane Biopharma changes the date for Interim and Year-end Report

© Modular Finance, source Nordic Press Releases